Liposarcoma market growth is driven by increasing awareness and earlier diagnosis, expanding the pool of treatable patients. Advances in molecular profiling and targeted therapies are attracting investment and clinical development. Furthermore, the launch of emerging therapies, including INT230-6, Alrizomadlin (APG-115), BOXR1030, BTX-A51, CEB-01, Letetresgene Autoleucel, and others, will propel the market.
Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities
Liposarcoma, a tumor arising from lipoblasts, is an uncommon mesenchymal neoplasm that affects deep soft tissues such as the esophagus, retroperitoneum, and popliteal fossa. The incidence of liposarcoma across body regions varies by subtype. For instance, dedifferentiated liposarcoma is predominantly found in the retroperitoneum, whereas myxoid liposarcoma more commonly affects the lower limbs. In contrast, esophageal liposarcoma is extremely rare. When it does occur, it generally presents as a slow-growing tumor in the upper part of the esophagus. Most esophageal cases are well-differentiated, localized to the esophagus, carry a low risk of metastasis, but have a high rate of local recurrence —around 10% —which can occur even decades, up to 25 years, after surgical removal.
Emerging therapeutics
The approval by the U.S. Food and Drug Administration (FDA) of afamitresgene autoleucel (Tecelra®; Adaptimmune) for the treatment of advanced synovial sarcoma and, in addition, the breakthrough designation of letetresgene autoleucel* [1] for the treatment of myxoid/round cell liposarcoma signify major developments in the emergence of novel therapeutics.
Chimeric antigen receptor T-cell (CAR T-cell) therapies primarily target B7H3, GD2, FGFR4, and HER2, and include novel approaches such as dual antigen targeting and safety switches. Tumour infiltrating lymphocyte (TIL-) therapies, including lifileucel, are under investigation with checkpoint inhibitors or other oncolytic agents to enhance efficacy and manage toxicity. Finally, adoptive T-cell therapy demonstrates early promise in sarcomas, particularly TCR-T therapy.[2]
However, observed challenges include HLA restriction**, tumour heterogeneity, and manufacturing complexity. Future strategies involving novel antigens, multi-targeting, and combinatorial regimens could broaden patient eligibility and improve therapeutic outcomes. [2]
Emerging therapeutic opportunities in liposarcoma are increasingly driven by modulation of the tumor–host immune response. In particular, stimulating the immune system using the cancer-testis antigen NY-ESO-1 as a vaccine target may hold potential in MRCL 60. Recent studies have highlighted important trends in the management and prognosis of liposarcoma, which are influenced by factors such as tumor subtype, grade, histology, and the surrounding immune environment.
Surgical resection continues to be the mainstay for tumors like retroperitoneal liposarcoma and retroperitoneal sarcoma, though the risk of local recurrence remains substantial. Advances in medical technology are anticipated to enhance minimally invasive surgery and precision radiotherapy, thereby reducing complications and side effects and improving patient quality of life.
Adjuvant radiotherapy, both pre- and post-surgery, alongside emerging immunotherapies, may increasingly become integral components of treatment strategies. Preoperative radiotherapy has demonstrated effectiveness in reducing local recurrence, while the benefits of perioperative radiotherapy remain uncertain. Immunotherapy has shown promising results in certain studies, particularly in patients with elevated PD-L1 and PD-L2 expression. Future research is expected to explore immunotherapy mechanisms in greater depth and identify more precise prognostic markers, enabling personalized treatment approaches that enhance survival and quality of life.
Additionally, studies in patients with retroperitoneal liposarcoma and sarcoma suggest that peripheral blood inflammatory markers and specific tumor tissue biomarkers could help predict early recurrence and postoperative survival. Advances in tumor immunology and genomics, combined with ongoing development of immunotherapies and targeted therapies, are paving the way for highly individualized treatment strategies tailored to tumor subtypes.
Clinical development
Pharmaceutical companies developing therapies for treating liposarcoma include Intensity Therapeutics (INT230-6), Ascentage Pharma (Alrizomadlin [APG-115]), Sotio (BOXR1030), CEBIOTEX (CEB-01), Edgewood Oncology (BTX-A51), Adaptimmune (Letetresgene Autoleucel [lete-cel]), and others with their candidates in different stages of clinical development.
Intensity Therapeutics’ leading proprietary investigational product candidate, INT230-6, is formulated for direct intratumoral administration. It was developed using the company’s proprietary DfuseRx technology platform and has received orphan drug designation for its components in the treatment of sarcoma.
As of a November 2024 press release, the INVINCIBLE-3 study (NCT06263231) is actively recruiting, targeting 333 patients with leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma. The study has obtained regulatory approvals in the United States, Canada, Europe, and Australia.
However, according to Intensity Therapeutics’ Q2 2025 presentation, the INVINCIBLE-3 study was placed on hold in March 2025 (Q1 2025) due to pending funding, with plans to resume enrollment anticipated in 2026.
Separately, Sotio’s BOXR1030 is a next-generation CAR T-cell therapy designed to enhance T cell metabolism within the solid tumor microenvironment. Its initial clinical indications include hepatocellular carcinoma, lung squamous cell carcinoma, and myxoid/round cell liposarcoma.
The anticipated launch of these emerging therapies is poised to transform the liposarcoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the liposarcoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
_
Note:* Letetresgene autoleucel was originally developed by Adaptimmune Therapeutics, which entered into a collaboration with GlaxoSmithKline (GSK) for its further development. In 2023, the program was returned to Adaptimmune, which then sold its cell therapy assets, including lete-cel, to US WorldMeds in July 2025. US WorldMeds plans to continue the development and aims to bring the therapy to the U.S. market, with potential regulatory approval anticipated in 2026 for the treatment of advanced synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). AGC Biologics, a contract development and manufacturing organization (CDMO), manufactures the lentiviral vectors used to produce lete-cel in support of the regulatory submissions.
** HLA restriction is an immunological concept where a T-cell can only recognize a foreign antigen when it is presented by a specific type of human leukocyte antigen (HLA) molecule on the surface of a cell. This is because T-cells have a specific receptor that binds only to a particular HLA molecule and a peptide fragment of the antigen. It is a fundamental mechanism of the adaptive immune system for distinguishing “self” from “non-self” and responding to pathogens.
Clinical trials
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) – ClinicalTrials.gov ID NCT05120271
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma – ClinicalTrials.gov ID NCT06414434
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) (INVINCIBLE-3) – ClinicalTrials.gov ID NCT06263231
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma – ClinicalTrials.gov ID NCT02992743
Highlights of Prescribing Information
Afamitresgene autoleucel (Tecelra®; Adaptimmune)[Prescribing Information]
Reference
[1] D’Angelo SP, Druta M, Van Tine BA, Liebner D, Schuetze SM, Tap WD, Preston J, Goodison S, D’Souza JW, Kapoor GS, Suchindran S, Zajic S, Bhaskar A, Kaczynski H, Kim J, Klohe E, Corigliano E, Eleftheriadou I, Nathenson MJ, Somaiah N. Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma. J Clin Oncol. 2025 May 20;43(15):1777-1788. doi: 10.1200/JCO-24-01466. Epub 2025 Jan 21. PMID: 39836945; PMCID: PMC12084024.
[2] Kucharczyk M, Hatipoglu E, Jones RL, Huang PH. Adoptive T-Cell Therapy in Sarcomas. Curr Oncol Rep. 2025 Oct;27(10):1131-1143. doi: 10.1007/s11912-025-01706-x. Epub 2025 Aug 14. PMID: 40810970.
Featured image © 2023 – 2025 licensed under the Unsplash+ License. Used with permission.
DOI
